Clinical Trial Update: Use of Baricitenib to Maintain of Remission [Phase 2, Phase 3]

View source ↗

Summary

Clinical trial update for Baricitenib aimed at maintaining remission in lupus and nephritis in Phase 2/Phase 3.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nephritis
• Systemic Lupus Erythematosus

Drugs mentioned

• Baricitenib

Snippet

Sponsor: Assiut University | Conditions: Lupus or SLE, Nephritis | Phase 2, Phase 3 | Status: UNKNOWN